After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

The asthma medication reduces congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in a ...

The AstraZeneca PLC ADR AZN rose 1.79% to $75.57 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.22% to ...

Carlsbad: Ionis Pharma and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be ...

Astrazeneca (AZN) ended the recent trading session at $75.57, demonstrating a +1.79% swing from the preceding day's closing price. This change outpaced the S&P 500's 0.49% gain on the day. On the ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...